Cargando…
Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002)
BACKGROUND: This study was designed to explore whether an intensified chemoradiotherapy (CRT) led to a better clinical outcome in locally advanced rectal cancer. METHODS: Patients with stage II/III rectal cancer were randomly allocated to receive either pelvic intensity-modulated radiation therapy (...
Autores principales: | Wang, Jingwen, Guan, Yun, Gu, Weilie, Yan, Senxiang, Zhou, Juying, Huang, Dan, Tong, Tong, Li, Chao, Cai, Sanjun, Zhang, Zhen, Zhu, Ji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883699/ https://www.ncbi.nlm.nih.gov/pubmed/31783766 http://dx.doi.org/10.1186/s13014-019-1420-z |
Ejemplares similares
-
Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study
por: Zhu, Ji, et al.
Publicado: (2014) -
A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma
por: Zhu, Ji, et al.
Publicado: (2013) -
Comparing neoadjuvant long-course chemoradiotherapy with short-course radiotherapy in rectal cancer
por: Wang, Jian, et al.
Publicado: (2021) -
Neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer: A new era for anal preservation
por: Wang, Yaqi, et al.
Publicado: (2022) -
Factors influencing downstaging after neoadjuvant long-course chemoradiotherapy in rectal carcinoma
por: Kohl, Valerie K. B., et al.
Publicado: (2022)